Successful rituximab monotherapy for API2-MALT1 fusion positive primary mucosa-associated lymphoid tissue lymphoma of the transverse colon in a patient with liver cirrhosis.
Masayoshi
M
Yamada
Hiromu
H
Kawahara
Hisakazu
H
Shiroeda
Mutsumi
M
Tsuchishima
Yasufumi
Y
Masaki
Katsuaki
K
Sato
Shujiro
S
Takase
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000737:chemistry / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000737:chemistry / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000032:analysis*; D000069283:Rituximab
C415943:API2-MALT1 fusion protein, human; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; D000069283:Rituximab